219 related articles for article (PubMed ID: 6250470)
1. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
Jorgensen JH; Crawford SA; Alexander GA
Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
[TBL] [Abstract][Full Text] [Related]
2. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
Hall WH; Opfer BJ; Gerding DN
Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of cefotaxime and selected beta-lactam antibiotics against Haemophilus influenzae and aerobic gram-negative bacilli.
Dabernat HJ; Delmas C
Rev Infect Dis; 1982; 4 Suppl():S401-5. PubMed ID: 6294790
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of a new 1-oxa cephalosporin compound.
Downs JT; Andriole VT
Yale J Biol Med; 1980; 53(2):149-59. PubMed ID: 6446810
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
Perrymann F; Flournoy DJ; Qadri SM
Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.
Lang SD; Edwards DJ; Durack DT
Antimicrob Agents Chemother; 1980 Mar; 17(3):488-93. PubMed ID: 6252831
[TBL] [Abstract][Full Text] [Related]
8. [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
Baumgärtner M; Dickgiesser N; Müller S; Wundt W
Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of cephalothin-resistant gram-negative bacilli to piperacillin, cefuroxime, and other selected antibiotics.
George WL; Lewis RP; Meyer RD
Antimicrob Agents Chemother; 1978 Mar; 13(3):484-9. PubMed ID: 122524
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial activity of moxalactam (LY-127935) compared with cefotaxime and other beta-lactam antibiotics against clinical isolates of enterobacteriacea and non-fermenters.
Verbist L
Arzneimittelforschung; 1981; 31(6):982-6. PubMed ID: 6266430
[TBL] [Abstract][Full Text] [Related]
11. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.
Jones RN; Fuchs PC; Sommers HM; Gavan TL; Barry AL; Gerlach EH
Antimicrob Agents Chemother; 1980 Apr; 17(4):750-6. PubMed ID: 6446880
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies of moxalactam (LY127935), a new beta-lactam antibiotic with significant activity against gram-negative bacteria.
DeMaria A; Alvarez S; Klein JO; McCabe WR
Infection; 1980; 8 Suppl 3():S 261-7. PubMed ID: 6447671
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
Pusztai-Markos Z; Pranada F
Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.
Kurtz TO; Winston DJ; Hindler JA; Young LS; Hewitt WL; Martin WJ
Antimicrob Agents Chemother; 1980 Oct; 18(4):645-8. PubMed ID: 6255864
[TBL] [Abstract][Full Text] [Related]
15. The sensitivity of gentamicin-resistant gram-negative bacilli to cefotaxime, other cephalosporins and aminoglycosides.
Stephens M; Potten M; Bint AJ
Infection; 1979; 7(3):109-12. PubMed ID: 478651
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of the novel oxa-beta-lactam antibiotic moxalactam (LY 127935) against dense populations of selected Gram-negative bacilli.
Greenwood D; Eley A; Pearson N; O'Grady F
J Antimicrob Chemother; 1981 Apr; 7(4):353-62. PubMed ID: 6265424
[TBL] [Abstract][Full Text] [Related]
17. In vitro comparison of three new cephalosporins: LY-127935, cefotaxime and cefoperazone.
Trager GM; White GW; Zimelis VM; Bryk DA; Panwalker AP
Chemotherapy; 1981; 27(1):34-8. PubMed ID: 6260435
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.
McNamara BT; Meyer RD; Pasiecznik KA
Antimicrob Agents Chemother; 1982 May; 21(5):753-7. PubMed ID: 6213196
[TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of gentamicin-resistant Gram-negative aerobic bacilli to cefotetan and other beta-lactams.
Hart CA; Percival A
J Antimicrob Chemother; 1983 Jan; 11 Suppl():95-101. PubMed ID: 6573329
[TBL] [Abstract][Full Text] [Related]
20. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
Jorgensen JH; Crawford SA; Alexander GA
Antimicrob Agents Chemother; 1980 May; 17(5):901-4. PubMed ID: 6249198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
